NetworkNewsBreaks

FridayJun 09, 2017 2:48 pm

NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Raises $5M in Private Placement; Proceeds will Fund Continued Development of Lead Candidate

AzurRx BioPharma (NASDAQ: AZRX) this morning announced the closing of a $5 million private placement that the company says will fund the continuation of its lead development program. “We are very grateful for the continued support of our investors and thrilled that the financing was over-subscribed,” AzurRx president and CEO Thijs Spoor stated in the news release. “This financing allows us to continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. In April, AzurRx said early results of its phase IIa trial of MS1819 indicated a favorable safety…

Continue Reading

FridayJun 09, 2017 12:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 9, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: CANN 8.40% – News: Acquires GC Finance Arizona, LLC IPIX 4.76% – News: Changes name and ticker PPCB 4.35% – News: Receives written opinion from an International Search Authority regarding PCT application EGLE 3.31% – News: Takes delivery of M/V Fairfield Eagle CIIX 1.90% – News: Highlighted in published CFN Media Group article AEZS 1.87% – News: Presenting at the 2017 Marcum MicroCap Conference on June 16 SHOS 1.79% – News: Announces multiple grand…

Continue Reading

FridayJun 09, 2017 12:22 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $14 on shares of Novocure’s (NASDAQ: NVCR) stock following the company’s news that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM). The analyst said the additional coverage for Optune should result in a higher percentage of accrual-based revenue over time. The positive decision from HCSC brings the count of covered Americans to 204 million and is effective as of June 15, 2017. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment utilizing…

Continue Reading

FridayJun 09, 2017 12:20 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Following Revance Therapeutics, Inc.’s (NASDAQ: RVNC) report of positive results from its phase 2 clinical study of RT002 to treat moderate-to-severe isolated cervical dystonia (CD), Aegis Capital reiterated its ‘Buy’ rating and price target of $36 on shares of the company’s stock. Additionally, Revance is in the process of enrolling for its pivotal, phase 3 Sakura trials. The identical trials taking place in the U.S. and Canada will randomize subjects 2:1 to receive either RT002 or placebo. The analyst noted that based off of the results seen in the phase 2 CD trial, they believe it is likely that the…

Continue Reading

FridayJun 09, 2017 9:23 am

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) O2O Platform Mitigates SEO Burden and Helps SMEs Better Utilize E-Commerce

The Internet has been both a help and a hindrance to retailers – greatly extending their marketing reach and helping them target new customers, yet enabling faraway businesses to also beguile their customer base. Another challenge presented by the Internet is the difficulty of being visible within the sea of websites – more than 1.2 billion and quickly counting – which is where companies like Moxian (NASDAQ: MOXC) come in, offering solutions like the O2O Moxian+ platform to help small and medium-sized enterprises (SMEs) utilize e-commerce to drive customers to their brick-and-mortar locations and to cut down on the need…

Continue Reading

FridayJun 09, 2017 9:20 am

NetworkNewsBreaks – Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Steps Up Exploration Efforts in Wake of Chinese Production Cuts

As China recently increased its import of zinc in the wake of production halts – part of an environmental crackdown on China’s steel industry – global zinc prices subsequently soared. With worldwide zinc inventories already under pressure due to increasing demand, China’s efforts to curb zinc and nickel production will likely continue significantly impacting the global supply, and zinc exploration corporations like Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) are hastening to step up their efforts to find deposits and help slake this global shortage. “China’s move is likely to drive zinc demand even higher. According to the International Lead…

Continue Reading

ThursdayJun 08, 2017 1:22 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 8, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NFEC 13.53% – News: Conducts business visit in India ADAD 10.26% – News: Receives Q1 2017 update from Fingerprint Play NXTD 7.05% – News: Fit Pay receives approval as a Visa Token Service provider NMRX 5.62% – News: Closes $13.5M note purchase agreement with Hale Capital Partners STLT 5.11% – News: Reaches agreement with former CEO to return 1.6M shares UONE 4.76% – News: CASSIUS releases June 2017 cover SPYR 4.40% – News: Inks…

Continue Reading

ThursdayJun 08, 2017 1:21 pm

NetworkNewsBreaks – Grey Cloak Tech (GRCK) Enables Integration of Brick-and-Mortar and E-Commerce Omni-Channel Shopping

Now a dual-faceted company following its March 2017 takeover of ShareRails and its cloud-based software, Grey Cloak Tech (OTC: GRCK) is poised to play a significant role as major retailers seek to successfully integrate their physical stores with e-commerce to keep stride with the changing retail market. The proprietary software offered through ShareRails presents a promising solution in the battle of brick-and-mortar stores versus online companies, enabling storefront merchants to compete in the omni-channel shopping world and drive business to their physical locations through the use of e-commerce tools. “ShareRails’ proprietary software could be a key element in the survival…

Continue Reading

ThursdayJun 08, 2017 11:45 am

NetworkNewsBreaks – AVEO Oncology’s (NASDAQ: AVEO) Phase 1/2 TiNivo Trial Advances to Phase 2

AVEO Oncology (NASDAQ: AVEO) this morning said it has progressed to the phase 2 portion of its phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s Opdivo® in subjects with advanced renal cell carcinoma (RCC). The advancement follows the successful completion of the phase 1 dose escalation portion of the trial, results of which will be submitted for presentation at an upcoming scientific meeting. “As our registration strategy for single agent tivozanib reaches key inflection points, with a European regulatory decision expected in the near-term and readout of our US registration-directed TIVO-3 study expected in the first…

Continue Reading

ThursdayJun 08, 2017 11:05 am

NetworkNewsBreaks – Amedica Corporation (NASDAQ: AMDA) Releases Preliminary Earnings Report for FY2016

Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, this morning announced its preliminary earnings report for the fourth quarter and fiscal year ended December 31, 2016, and provided a business updated related to its strategy and recent developments. Among the highlights, Amedica reported preliminary revenue of $3.6 million for the fourth quarter of 2016 and $15.2 million for the full year. Preliminary GAAP net loss for the 12-month period was $1.19 per share, down from a net loss of $5.50 per share in 2015. Looking ahead, Amedica notes that it expects to complete…

Continue Reading